QIAGEN
Financial Report 2019
- 2019 results reflect a year of change and transformation
- Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion
- Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018
- Adjusted operating income of $421.8 million, margin at 28% of sales
- Free cash flow of $212.9 million in 2019
- Portfolio expansion across continuum from Life Sciences to Molecular Diagnostics